Beilu Pharma(SZ:300016)2024-11-01 09:26Financial Performance - In the first three quarters of 2024, the company achieved an operating income of 730 million CNY, representing a year-on-year growth of 12.30% [1] - The net profit attributable to shareholders reached 24.39 million CNY, with a staggering increase of 1156.34% compared to the same period last year [1] - The net profit after deducting non-recurring gains and losses was 25.22 million CNY, up by 275.59% year-on-year [1] Product Sales - The sales of diabetes products, including Glimepiride tablets and Repaglinide tablets, have shown significant growth, providing stable profit support and ensuring good cash flow [2] - The company plans to continue its efforts in securing supply and expanding retail channels for diabetes products [2] R&D Strategy - The company has integrated its R&D resources by merging Beilu Research Institute with Beijing Aipikes Pharmaceutical R&D Co., aiming for more efficient and professional operations [2] - Key areas of focus for R&D include contrast agents, central nervous system, endocrine, digestive, vitamins, and topical formulations [2] International Market Expansion - The company has successfully expanded its overseas market, with products sold in 26 countries and an additional 30 countries or regions in the registration process [2] - The production line for contrast agents has passed the Brazilian National Health Surveillance Agency's approval, facilitating further market expansion in Brazil and other international markets [3] Production Capacity Development - The Cangzhou Phase III raw material production project was completed in September 2024, with plans to produce gadolinium-based raw materials and other in-development pharmaceuticals [3] - The Bozhou production base construction is underway, which will enhance the company's capabilities in traditional Chinese medicine and various pharmaceutical forms [3]